Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

Next Previous
Trial Profile

A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mometasone (Primary)
  • Indications Rhinosinusitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ENLIGHTEN 2; ENLIGHTEN II
  • Sponsors Lyra Therapeutics

Most Recent Events

  • 12 Nov 2025 According to Lyra Therapeutics media release, company presented the positive ENLIGHTEN 2 Phase 3 results as a Late-Breaking Scientific Oral Presentation at the Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) in October 2025.
  • 06 Oct 2025 According to Lyra Therapeutics media release, data from this trial will be presented at the Annual Meeting of the American Academy of Otolaryngology Head and Neck Surgery (AAO HNS
  • 12 Aug 2025 According to a Lyra Therapeutics media release, company reengaged with the U.S. Food and Drug Administration (FDA) following the positive results from the ENLIGHTEN 2 Phase 3 study in early June. The Company is preparing for an upcoming Type C meeting with the FDA in the second half of 2025, in order to align on a path forward for an NDA submission for LYR-210 as a treatment for CRS patients without nasal polyps.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top